Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review

  • ID: 2606941
  • SWOT Analysis
  • 53 pages
  • GlobalData
  • Alkermes plc
1 of 5

FEATURED COMPANIES

  • Biogen Inc
  • Eli Lilly and Co
  • EMD Serono Inc
  • Indivior Plc
  • Novartis AG
  • Novo Nordisk AS
  • MORE
Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. The company’s proprietary products include Aristada, an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, the only once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants license under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to wholesalers, specialty distributors and specialty pharmacies. The company also has a clinical pipeline of products that address CNS disorders such as multiple sclerosis, schizophrenia, depression and addiction. Alkermes is headquartered in Dublin, Ireland.

Alkermes Plc Key Recent Developments

Mar 01, 2018: Alkermes Names James Robinson as President and Chief Operating Officer
Feb 14, 2018: Alkermes Names Shane Cooke As Board Director
Feb 14, 2018: Alkermes Reports Q4 2017 Financial Results
Feb 01, 2018: Alkermes in Athlone to lay off up to 30 workers by June
Nov 09, 2017: Alkermes Reveals Recipients of the 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biogen Inc
  • Eli Lilly and Co
  • EMD Serono Inc
  • Indivior Plc
  • Novartis AG
  • Novo Nordisk AS
  • MORE
Section 1 - About the Company
  • Alkermes Plc - Key Facts
  • Alkermes Plc - Key Employees
  • Alkermes Plc - Key Employee Biographies
  • Alkermes Plc - Major Products and Services
  • Alkermes Plc - History
  • Alkermes Plc - Company Statement
  • Alkermes Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Alkermes Plc - Business Description
  • Geographical Segment: Ireland
  • Performance
  • Geographical Segment: Rest of world
  • Performance
  • Geographical Segment: US
  • Performance
  • R&D Overview
  • Alkermes Plc - Corporate Strategy
  • Alkermes Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Alkermes Plc - Strengths
  • Alkermes Plc - Weaknesses
  • Alkermes Plc - Opportunities
  • Alkermes Plc - Threats
  • Alkermes Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Alkermes Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Nov 09, 2017: Alkermes Calls for Impartial National Review of Scientific Data Supporting the Use of FDA-Approved Treatment Options for Opioid Dependence
  • Nov 09, 2017: Alkermes Reveals Recipients of the 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders
  • Oct 26, 2017: Alkermes Reports Third Quarter 2017 Financial Results
  • Sep 28, 2017: Alkermes Participates in President’s Commission Meeting on Combating Drug Addiction and the Opioid Crisis
  • Sep 06, 2017: Alkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders
  • Sep 05, 2017: Alkermes to Present Clinical and Real-World Data at Upcoming 30th Annual Psych Congress
  • Jul 27, 2017: Alkermes Reports Second Quarter 2017 Financial Results
  • May 30, 2017: Alkermes Appoints Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President, Clinical Development and Medical Affairs
  • Apr 27, 2017: Alkermes Reports First Quarter 2017 Financial Results
  • Feb 15, 2017: Alkermes Reports Financial Results for the Year Ended Dec. 31, 2016 and Provides Financial Expectations for 2017
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Alkermes Plc, Key Facts
  • Alkermes Plc, Key Employees
  • Alkermes Plc, Key Employee Biographies
  • Alkermes Plc, Major Products and Services
  • Alkermes Plc, History
  • Alkermes Plc, Other Locations
  • Alkermes Plc, Subsidiaries
  • Alkermes Plc, Key Competitors
  • Alkermes Plc, Ratios based on current share price
  • Alkermes Plc, Annual Ratios
  • Alkermes Plc, Annual Ratios
  • Alkermes Plc, Annual Ratios
  • Alkermes Plc, Interim Ratios
  • Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Alkermes Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Alkermes Plc, Performance Chart (2013-2017)
  • Alkermes Plc, Ratio Charts
  • Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Alkermes Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Indivior Plc
  • Orexo US Inc
  • Sanofi
  • Novo Nordisk AS
  • Braeburn Pharmaceuticals Inc
  • Biogen Inc
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • Eli Lilly and Co
  • EMD Serono Inc
  • Otsuka Pharmaceutical Co Ltd
  • BioDelivery Sciences International Inc
  • Bayer HealthCare Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll